Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Cytomegalovirus Infections Clinical Trial

Official title:

Open Label Trial of Tolerability and Efficacy of Oral Letermovir for CMV Prophylaxis Among Heart and Lung Transplant Recipients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06066957
• Other study ID #: 853851
• Status: Recruiting
• Phase: Phase 2
• Start date: April 4, 2024
• Est. completion date: August 15, 2026

Study information

• Verified date: April 2024
• Source: University of Pennsylvania
• Contact: Kathryn Whitaker, MD
• Phone: 267-581-2135
• Email: Kathryn.Whitaker[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients and compare it to the efficacy of valganciclovir historical controls. The study hypotheses are:

1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients

2. Letermovir will be better tolerated than valganciclovir for CMV prophylaxis in heart and lung transplant recipients, with a higher proportion of days of completed therapy with correct dosing during the planned prophylaxis period

3. Letermovir will have a lower rate of neutropenia than valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients

4. Incorrect renal dosing will occur less frequently with letermovir than with valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients

Description:

This study is a prospective cohort design. Subjects exposed to letermovir for CMV prophylaxis following heart or lung transplantation will be compared with those who received standard valganciclovir prophylaxis in the two years before the study began (referred to as the "pre-intervention" period). The goal is to evaluate the efficacy and tolerability of letermovir.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: August 15, 2026
• Est. primary completion date: August 15, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Heart or Lung transplant recipient

• Donor and/or Recipient CMV seropositive (defined by positive IgG) within 1 year prior to transplantation

• Able to start oral CMV prophylaxis within 14 days of transplantation

• Males at birth agree to use contraception during the treatment period, and for at least 90 days after the last dose of study treatment, and refrain from donating sperm during this period

• Female at birth is not pregnant or breastfeeding. If of childbearing potential, agrees to follow the contraception guidance during the treatment period and for at least 90 days after the last dose of study treatment

• A male or female subject who is of reproductive potential agrees to true abstinence or to use (or have their partner use) 1 acceptable method of birth control starting from the time of consent through 90 days after the last dose of study therapy. True abstinence is defined as abstinence in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only during ovulation period, use of symptothermal method, use of post-ovulation methods) and withdrawal are not acceptable methods of contraception. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, and vasectomy OR use of appropriate double barrier contraception as per local regulations or guidelines. Hormonal contraceptives (e.g., birth control pills, transdermal patch, or injectables) are unacceptable methods of birth control for use in this study because it is not known whether these methods are affected by co-administration of letermovir.

Exclusion Criteria:

• Any prior solid organ transplant

• Dual organ transplantation

• Prior treated CMV infection

• Unknown CMV serostatus of the donor or recipient

• Suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations and/or acyclovir formulations

• CrCl <10 mL/minute, using Cockcroft-Gault equation, or renal replacement therapy at the time of enrollment

• Child-Pugh Class C severe hepatic insufficiency at enrollment

• Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 x the upper limit of normal (ULN) or serum total bilirubin > 2.5 x ULN. Note: Subjects who meet this exclusion criterion may, at the discretion of the investigator, have one repeat set of relevant labs done. If the repeat value does not meet this criterion, they may continue in the enrollment process

• Both moderate hepatic insufficiency AND moderate renal insufficiency. Note: Moderate hepatic insufficiency is defined as Child Pugh Class B; moderate renal insufficiency is defined as a creatinine clearance less than 50 mL/min, as calculated by the Cockcroft-Gault equation

• Neutropenia, defined as absolute neutrophil count <1,500/microliter, at the time of enrollment

• Severe thrombocytopenia, defined as platelets <50,000/microliter, at the time of enrollment

• Any uncontrolled infection on the day of enrollment

• Documented positive results for human immunodeficiency virus antibody (HIV-Ab) test at any time prior to enrollment, or for hepatitis C virus antibody (HCV-Ab) and with detectable HCV ribonucleic acid (RNA) within 90 days prior to enrollment, or hepatitis B surface antigen (HBsAg) within 90 days prior to enrollment.

• History of malignancy =5 years prior to signing informed consent, with the exception of localized basal cell or squamous cell skin cancer

• Pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 90 days following cessation of study therapy.

• Expecting to donate eggs or sperm starting from the time of consent through at least 90 days following cessation of study therapy.

• Received within 30 days prior to enrollment or plans to receive during the study any of the following anti-CMV IgG antibody treatment or anti-CMV drug therapy including the following: Cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.

• Received >14 days of IV ganciclovir prior to initiation of study drug or plans to receive during the study any of the following anti-CMV drug therapy: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, famciclovir.

• Currently participating or has participated in a study with an unapproved investigational compound within 28 days, or 5× half-life of the investigational compound whichever is longer, of initial dosing on this study

• Previously participated in this study or any other study involving letermovir

• Previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study.

• For unexposed subjects, any letermovir exposure

• Are unable to take medications orally by day 14 post-transplant

Related Conditions & MeSH terms

• Cytomegalovirus Infections
• Transplant-Related Disorder

Intervention

Drug:
• Letermovir 480 MG [Prevymis]
Letermovir for CMV prophylaxis in thoracic organ transplant recipients. Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7. Letermovir is dosed at 480mg daily for patients with CrCl >10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up.

Locations

Country	Name	City	State
United States	Penn Medicine at the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
University of Pennsylvania	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CMV viral load	CMV viremia with CMV viral load >1,000, CMV syndrome, or tissue invasive CMV disease.	Prophylaxis period plus 180 days
Primary	Proportion of days during which appropriately renally-dosed prophylaxis	Proportion of days during which appropriately-dosed prophylaxis during the planned treatment course.	90 to 365 days post intervention
Secondary	Frequency of Acute cellular rejection	The proportion of subjects who develop biopsy-proven acute cellular rejection	Prophylaxis period plus 180 days
Secondary	Proportion of subjects who develop CMV resistance	CMV resistance will be determined by the presence of a clinically significant mutation on genomic sequencing	Prophylaxis period plus 180 days
Secondary	Proportion of subjects who develop neutropenia	Proportion of subjects who develop Neutropenia (absolute neutrophil count (ANC) less than 1,500/microliter)	90 to 365 days of prophylaxis period
Secondary	Proportion of subjects who develop severe thrombocytopenia (platelet count less than 50,000/microliter)	Proportion of subjects who develop severe thrombocytopenia (platelet count less than 50,000/microliter)	90 to 365 days of prophylaxis period
Secondary	Proportion of subjects with Unplanned discontinuation of MMF or azathioprine	Proportion of subjects with Unplanned discontinuation of MMF or azathioprine	90 to 365 days of prophylaxis period
Secondary	Number subjects with Incorrect renal dosing at any point during the planned prophylaxis period (measured as a binary variable, where the outcome is met if the recipient receives any days of incorrect dosing per their GFR).	Number subjects with Incorrect renal dosing at any point during the planned prophylaxis period (measured as a binary variable, where the outcome is met if the recipient receives any days of incorrect dosing per their GFR).	90 to 365 days of prophylaxis period